Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
Development and internal validation of machine learning–based models and external validation of existing risk scores for outcome prediction in patients with ischaemic stroke
4
Zitationen
15
Autoren
2023
Jahr
Abstract
Aims: We developed new machine learning (ML) models and externally validated existing statistical models [ischaemic stroke predictive risk score (iScore) and totalled health risks in vascular events (THRIVE) scores] for predicting the composite of recurrent stroke or all-cause mortality at 90 days and at 3 years after hospitalization for first acute ischaemic stroke (AIS). Methods and results: In adults hospitalized with AIS from January 2005 to November 2016, with follow-up until November 2019, we developed three ML models [random forest (RF), support vector machine (SVM), and extreme gradient boosting (XGBOOST)] and externally validated the iScore and THRIVE scores for predicting the composite outcomes after AIS hospitalization, using data from 721 patients and 90 potential predictor variables. At 90 days and 3 years, 11 and 34% of patients, respectively, reached the composite outcome. For the 90-day prediction, the area under the receiver operating characteristic curve (AUC) was 0.779 for RF, 0.771 for SVM, 0.772 for XGBOOST, 0.720 for iScore, and 0.664 for THRIVE. For 3-year prediction, the AUC was 0.743 for RF, 0.777 for SVM, 0.773 for XGBOOST, 0.710 for iScore, and 0.675 for THRIVE. Conclusion: The study provided three ML-based predictive models that achieved good discrimination and clinical usefulness in outcome prediction after AIS and broadened the application of the iScore and THRIVE scoring system for long-term outcome prediction. Our findings warrant comparative analyses of ML and existing statistical method-based risk prediction tools for outcome prediction after AIS in new data sets.
Ähnliche Arbeiten
Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment.
1993 · 12.177 Zit.
Correspondence - Tranexamic acid for traumatic brain injury
2005 · 11.727 Zit.
Tissue Plasminogen Activator for Acute Ischemic Stroke
1995 · 11.639 Zit.
Aspirin plus Clopidogrel as Secondary Prevention after Stroke or Transient Ischemic Attack: A Systematic Review and Meta-Analysis
2014 · 11.554 Zit.
Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies
2002 · 10.201 Zit.
Autoren
Institutionen
- Murdoch University(AU)
- Pennsylvania State University(US)
- Department of Public Health(MM)
- Penn State Milton S. Hershey Medical Center(US)
- Mayo Clinic in Arizona(US)
- Geisinger Neuroscience Institute(US)
- Geisinger Health System(US)
- Brigham and Women's Hospital(US)
- Harvard University(US)
- West Virginia University Hospitals(US)
- Mayo Clinic Health System(US)
- Mayo Clinic Hospital(US)
- Mayo Clinic(US)
- Mayo Clinic in Florida(US)
- St. Michael's Hospital(CA)
- University of Toronto(CA)